Vimal Kavuru, a director of Grace Therapeutics, Inc. (NASDAQ:GRCE), filed a Form 4 on September 21, 2026, disclosing the acquisition of a stock option granted on September 17, 2026.

Key Highlights

  • Option granted: Kavuru acquired a stock option (right to buy) covering 12,200 shares of Common Stock on September 17, 2026.
  • Exercise price: The option carries an exercise price of $2.13 per share.
  • Expiration date: The option expires on September 16, 2036.
  • Price paid: The option was acquired at a price of $0.
  • Vesting schedule: 50% of the option vests on the date of grant, with the remaining 50% vesting in substantially equal monthly installments over a 12-month period, subject to continuous service.
  • Resulting ownership: Kavuru beneficially owns 12,200 derivative securities following the transaction, held directly.

Stock Option Award to Grace Therapeutics Director Vimal Kavuru

According to the Form 4 filed with the SEC on September 21, 2026, Vimal Kavuru, who is identified as a director of Grace Therapeutics, Inc., received a stock option granting the right to buy 12,200 shares of Common Stock. The transaction date is listed as September 17, 2026, and the filing reports transaction code "A," indicating an acquisition. The option was received at a price of $0 and carries an exercise price of $2.13 per share.

The filing discloses that the option has an expiration date of September 16, 2036. As described in the explanation of responses, "50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date." Following this transaction, Kavuru's reported beneficial ownership of the derivative security stands at 12,200 shares, held directly.

The Form 4 was signed by Robert DelAversano as attorney-in-fact for Vimal Kavuru. No transactions in non-derivative securities were reported in Table I of the filing. Grace Therapeutics, Inc. is listed on NASDAQ under the ticker symbol GRCE, as stated on the filing's cover.

What Was Disclosed

The filing reports that director Vimal Kavuru acquired a stock option to purchase 12,200 shares of Grace Therapeutics Common Stock at $2.13 per share, granted September 17, 2026, expiring September 16, 2036, with a split vesting schedule over 12 months.